FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older |
7/19/2022 |
Opzelura |
ruxolitinib |
FDA approves treatment for chronic weight management in pediatric patients aged 12 years and older |
6/24/2022 |
Qsymia |
phentermine and topiramate |
FDA approves treatment for weight management in patients with Bardet-Biedl Syndrome aged 6 or older |
6/16/2022 |
Imcivree |
setmelanotide |
FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS) |
5/12/2022 |
Radicava ORS |
edaravone |
FDA approves new drug to improve heart function in adults with rare heart condition |
4/29/2022 |
Camzyos |
mavacamten |
FDA approves drug for treatment of seizures associated with rare disease in patients two years of age and older |
3/18/2022 |
Ztalmy |
ganaxolone |
FDA approves drug for adults with rare form of bone marrow disorder |
2/28/2022 |
Vonjo |
pacritinib |
FDA approves treatment for anemia in adults with rare inherited disorder |
2/17/2022 |
Pyrukynd |
mitapivat |
FDA approves treatment for adults with rare type of anemia |
2/4/2022 |
Enjaymo |
sutimlimab-jome |
FDA approves add-on therapy to lower cholesterol among certain high-risk adults |
12/22/2021 |
Leqvio |
inclisiran |
FDA approves drug to treat, help prevent types of blood clots in certain pediatric populations |
12/20/2021 |
Xarelto |
rivaroxaban |
FDA approves Tezspire as maintenance treatment for severe asthma |
12/17/2021 |
Tezspire |
tezepelumab-ekko |
FDA approves drug to treat sickle cell disease in patients aged 4 up to 11 years |
12/17/2021 |
Oxbryta |
voxelotor |
FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease |
12/15/2021 |
Tarpeyo |
budesonide |
FDA approves naloxone injection to counteract opioid overdoses |
10/15/2021 |
ZIMHI |
naloxone hydrochloride |
FDA approves add-on drug for adults with rare form of blood vessel inflammation |
10/13/2021 |
Tavneos |
avacopan |
FDA approves add-on drug for ages 10 & up with rare forms of high cholesterol |
9/24/2021 |
Repatha |
evolocumab |
FDA approves new use of transplant drug based on real-world evidence |
7/16/2021 |
Prograf |
tacrolimus |
FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes |
7/9/2021 |
Kerendia |
finerenone |
FDA approves therapy for pediatric patients with serious rare blood disease |
6/7/2021 |
Ultomiris |
ravulizumab-cwvz |
FDA approves drug to treat smallpox |
6/4/2021 |
Tembexa |
brincidofovir |
FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer |
5/27/2021 |
Pylarify |
piflufolastat F 18 |
FDA approves new treatment for adults with serious rare blood disease |
5/14/021 |
Empaveli |
pegcetacoplan |
FDA approves add-on therapy for patients with genetic form of severely high cholesterol |
4/1/2021 |
Praluent |
alirocumab |
FDA approves first treatment for disease that causes recurrent inflammation in sac surrounding heart |
3/18/2021 |
Arcalyst |
rilonacept |
FDA approves add-on therapy for patients with genetic form of severely high cholesterol |
2/11/2021 |
Evkeeza |
evinacumab-dgnb |
FDA approves treatment for ebola virus |
12/21/2020 |
Ebanga |
Ansuvimab-zykl |
FDA approves weight management drug for patients aged 12 and older |
12/4/2020 |
Saxenda |
liraglutide |
FDA approves first treatment for weight management for people with certain rare genetic conditions |
11/27/2020 |
Imcivree |
setmelanotide |
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness |
10/22/2020 |
Veklury |
remdesivir |
FDA approves weekly therapy for adult growth hormone deficiency |
9/1/2020 |
Sogroya |
somapacitan |
FDA approves new treatment for rare hereditary disease |
8/23/2018 |
Takhzyro |
lanadelumab |